Main Research Findings

1) Treatment with magnesium taurate was found to reduce the progression of cardiac toxicity and hypertension.

2) Magnesium taurate administration was shown to prevent cataractogenesis through the restoration of oxidative damage.

 

Selected Data
1) The research team of Shrivastava et al. investigated the antihypertensive and cardioprotective effects of magnesium taurate (MgT) in a rat model of cadmium chloride (CdCl₂)-induced hypertension and myocardial injury. The study was based on evidence that cadmium exposure can adversely affect the cardiovascular system through mechanisms involving oxidative stress, endothelial dysfunction, impaired nitric oxide availability, altered calcium signaling, and activation of the renin–angiotensin system. Because magnesium and taurine are both associated with cardiovascular regulation and antioxidant protection, the researchers examined whether combining these compounds as magnesium taurate could reduce the cardiovascular effects produced by chronic cadmium exposure [1].
The researchers used male Sprague Dawley rats weighing 120–150 g and approximately 12–15 weeks old. Animals were maintained under standardized laboratory conditions, including a temperature of 22 ± 2°C, humidity of 55 ± 5%, and a 12-hour light/dark cycle. Standard pellet food and water were provided ad libitum. Following a seven-day acclimatization period, baseline blood pressure was evaluated, and rats with normal blood pressure were selected for inclusion. The animals were then divided into five groups, with six animals in each group. Group I served as the normal control and received 0.3% carboxymethyl cellulose (CMC) orally at 10 ml/kg/day for four weeks. Groups II through V were used to establish the cadmium-induced hypertension model and received CdCl₂ at 0.5 mg/kg/day through intraperitoneal administration for four weeks. According to the experimental design, hypertension was established by the end of the second week.
After hypertension had been induced, the treatment phase began during the third week while CdCl₂ administration continued. Group II served as the toxic control and continued receiving CdCl₂ without additional treatment. Group III received amlodipine at 3 mg/kg/day orally and served as the standard-treatment group. Groups IV and V received magnesium taurate orally at doses of 2 mg/kg/day and 4 mg/kg/day, respectively. Therefore, the study allowed the investigators to compare two doses of MgT with both untreated cadmium exposure and an established antihypertensive drug. The MgT and amlodipine preparations were suspended in 0.3% CMC, while CdCl₂ was dissolved in distilled water. The appropriate doses were selected based on previous reports, and all treatments were administered daily between 10:00 and 11:00 a.m [1].
Blood pressure was monitored throughout the experiment to determine the effects of cadmium exposure and subsequent treatment. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) were measured every two weeks using a non-invasive CODA-08 Channel blood pressure system. At the conclusion of the four-week protocol, the animals were sacrificed and their hearts were removed for biochemical and histological assessment. The isolated hearts were washed with cold saline and homogenized at a concentration of 10% weight/volume using 0.1 M potassium phosphate buffer at pH 7.4. The homogenates were centrifuged at 10,000 rpm for one hour, and the resulting supernatants were collected and stored at 2–8°C until biochemical analyses were conducted.
The biochemical component of the study focused on myocardial antioxidant status and oxidative damage. The investigators measured glutathione peroxidase (GPx), catalase (CAT), and superoxide dismutase (SOD) as enzymatic antioxidant markers. Reduced glutathione (GSH) was measured as a nonenzymatic antioxidant using Ellman’s reagent. Malondialdehyde (MDA), an indicator of lipid peroxidation, was measured using a colorimetric method. These measurements were intended to determine whether chronic CdCl₂ exposure altered the antioxidant defenses of cardiac tissue and whether MgT treatment could restore these defenses while reducing lipid peroxidation [1].
Histopathological analysis was conducted to evaluate structural myocardial injury. One heart from each group was fixed in 10% buffered neutral formalin before being embedded in paraffin, sectioned, and stained with hematoxylin and eosin. The resulting slides were examined under a trinocular microscope at 10× and 40× magnifications. Cardiac injury was graded using a four-level scoring system. A score of 0 represented normal tissue without pathological changes, whereas score 1 represented mild focal myocyte injury and inflammation. Score 2 indicated moderate degeneration of cardiac muscle fibers, while score 3 represented marked damage involving loss of cross-striation, disruption of cardiomyocyte boundaries, degeneration of cardiac muscle fibers, necrosis, vacuolization, edema, fatty degeneration, and inflammatory-cell infiltration [1].
2) The study by the research team of Choudhary and Bodakhe investigated whether magnesium taurate (MgT) could protect against hypertension and cataract development produced by chronic cadmium chloride (CdCl₂) exposure. The investigators were particularly interested in the relationship between hypertension, oxidative stress, electrolyte disturbances, impaired ATPase activity, and cataractogenesis. Magnesium taurate was selected because it combines magnesium, which participates in calcium regulation, membrane function, smooth-muscle contraction, ATPase activity, and electrolyte homeostasis, with taurine, an abundant amino acid associated with antioxidant, membrane-stabilizing, osmoregulatory, and calcium-modulating effects. The researchers used a CdCl₂-induced hypertensive rat model because their previous work had demonstrated that chronic cadmium exposure produces hypertension while simultaneously increasing oxidative stress and disturbing electrolyte balance within the lens. The central experimental objective was therefore to determine whether MgT could reverse these changes and delay the development or progression of cataracts [2].
The experiment used male Sprague-Dawley albino rats that were 15–18 weeks old and weighed between 150 and 180 g. Animals were maintained under standardized laboratory conditions consisting of a temperature of approximately 22 ± 2 °C, relative humidity of 55 ± 5%, and a 12-hour light/dark cycle. They were provided standard pellet food and water ad libitum. Following a seven-day acclimatization period, animals were screened to ensure normal baseline blood pressure and ocular status. The rats were then randomly distributed into five experimental groups containing six animals each. The normal group received 0.3% carboxymethyl cellulose at 10 ml/kg/day orally and served as the non-hypertensive control. The hypertension control group received CdCl₂ at 0.5 mg/kg/day intraperitoneally. Two experimental groups received MgT orally at either 3 or 6 mg/kg/day concurrently with CdCl₂, while a standard-treatment group received amlodipine at 3 mg/kg/day orally together with CdCl₂. Amlodipine was included as the reference antihypertensive treatment because it is a calcium-channel blocker and had previously been shown to counteract CdCl₂-associated calcium-dependent hypertension.
The treatment period lasted six consecutive weeks. MgT and amlodipine were prepared as oral suspensions using carboxymethyl cellulose, whereas CdCl₂ was dissolved in distilled water for intraperitoneal administration. During the experiment, systolic blood pressure (SBP), diastolic blood pressure (DBP), and heart rate were measured every two weeks using a non-invasive CODA-08 blood-pressure system. Ocular examinations were also performed biweekly using a panoptic ophthalmoscope following pupil dilation with 1% tropicamide. Cataract development was categorized according to five stages representing increasing lens opacity: a clear normal lens, vacuole formation covering approximately half of the anterior pole, cortical opacity, hazy cortical and nuclear opacity, and mature cataract. Cataract incidence was calculated based on the number of eyes exhibiting each stage relative to the total number of eyes examined. At the end of six weeks, the lenses were removed through a posterior approach and visually assessed photographically against black paper. Clear lenses were considered normal, whereas cloudy or opaque lenses represented increasing lenticular damage [2].
After completion of the six-week treatment period, the animals were sacrificed and blood was collected by cardiac puncture. Serum was separated and stored at 2–8 °C for subsequent biochemical analyses. The eyeballs were removed, the lenses were dissected, washed in cold saline, and stored at −20 °C until analysis. Lens tissues were homogenized in ten volumes of 0.1 M potassium phosphate buffer at pH 7.0. Oxidative stress was assessed in both serum and lens tissue by measuring catalase (CAT), superoxide dismutase (SOD), glutathione peroxidase (GPx), reduced glutathione (GSH), and malondialdehyde (MDA). CAT activity was assessed through hydrogen peroxide decomposition, SOD through inhibition of nitroblue tetrazolium reduction, GPx through hydrogen-peroxide-dependent glutathione oxidation, and GSH using Ellman’s reagent. MDA, an indicator of lipid peroxidation, was quantified using a thiobarbituric-acid-reactive-substances method. These measurements allowed the researchers to determine whether CdCl₂-induced hypertension was accompanied by depletion of antioxidant defenses and increased lipid peroxidation and whether MgT could restore the antioxidant balance [2].
Additional biochemical measurements focused on structural and ionic changes within the lens. Total and soluble lens protein concentrations were measured using the Lowry method with bovine serum albumin as the calibration standard. Serum and lens sodium (Na⁺) and potassium (K⁺) concentrations were determined using a digital flame photometer, while calcium (Ca²⁺) was measured spectrophotometrically using diagnostic kits. The investigators also assessed two major ATP-dependent ion pumps, Ca²⁺ ATPase and Na⁺/K⁺ ATPase, because these enzymes are important for maintaining the ionic environment required for lens transparency. Ca²⁺ ATPase activity was determined by incubating lens homogenate with Tris-HCl buffer, CaCl₂, and ATP, followed by measurement of liberated phosphorus. Na⁺/K⁺ ATPase activity was evaluated using lens homogenate with Tris-HCl, magnesium sulfate, potassium chloride, sodium chloride, EDTA, and ATP, again quantifying liberated phosphorus spectrophotometrically [2].

 

Discussion
1) The results of the study by Shrivastava et al showed that CdCl₂ successfully produced significant hypertension and myocardial oxidative injury in the experimental rats. Animals receiving CdCl₂ demonstrated significant elevations in both systolic and diastolic blood pressure within two weeks when compared with the normal control group. Blood pressure continued to increase in the toxic-control group throughout the four-week experimental period. In contrast, when amlodipine or magnesium taurate was administered during the third and fourth weeks, both treatments significantly reduced SBP and DBP compared with the toxic-control group. These reductions were also statistically significant at P < 0.001. The researchers reported that MgT at 4 mg/kg/day produced the most pronounced antihypertensive effect and demonstrated greater activity than both the 3 mg/kg/day amlodipine treatment and the 2 mg/kg/day MgT dose [1].

 

Figure 1: Changes in systolic and diastolic blood pressure across the treatment period.
The biochemical findings demonstrated that chronic cadmium exposure substantially impaired myocardial antioxidant defenses. Compared with the normal group, CdCl₂-treated rats showed significant reductions in catalase, glutathione peroxidase, reduced glutathione, and superoxide dismutase. In the toxic-control group, CAT decreased to 11.20 ± 1.06 compared with 33.40 ± 2.08 in normal animals. GPx decreased from 2.40 ± 0.07 in the normal group to 0.94 ± 0.07 following CdCl₂ exposure. GSH declined from 6.95 ± 0.10 to 4.26 ± 0.05, while SOD decreased from 9.50 ± 0.54 to 3.82 ± 0.21. Each of these differences was statistically significant at P < 0.001. These results indicated that prolonged CdCl₂ administration was associated with considerable disruption of the myocardial antioxidant system.
Magnesium taurate substantially improved the antioxidant profile of cardiac tissue. Both MgT doses significantly increased CAT, GPx, GSH, and SOD relative to the toxic-control group. The researchers therefore concluded that MgT had a substantial capacity to restore myocardial antioxidant defenses, with effects broadly comparable to those produced by amlodipine. The effects of MgT on oxidative damage were further demonstrated by changes in malondialdehyde. The toxic-control group had a significantly elevated MDA concentration of 8.48 ± 0.29 compared with 5.30 ± 0.25 in the normal group. Treatment with amlodipine and both doses of MgT significantly decreased MDA relative to the toxic control. MDA concentrations were 6.76 ± 0.26 in the amlodipine group, 6.74 ± 0.26 in the 2 mg/kg MgT group, and 6.26 ± 0.30 in the 4 mg/kg MgT group. Thus, the higher MgT dose produced the greatest reduction in MDA among the MgT treatments and brought the marker closer to the normal value. These findings indicated that MgT reduced the lipid peroxidation associated with CdCl₂ exposure [1].
Histopathological examination supported the biochemical evidence of cardioprotection. Hearts from the normal control animals showed preserved myocardial architecture without detectable pathological abnormalities and received a damage score of 0. Conversely, cardiac tissue from the CdCl₂ toxic-control group exhibited marked myocardial injury and received a score of 3. The observed structural abnormalities included loss of cross-striation, disruption of cardiomyocyte boundaries, degeneration of cardiac muscle fibers, necrosis, vacuolization, fatty degeneration, edema, and inflammatory-cell infiltration. Treatment with amlodipine and MgT at 2 mg/kg/day reduced the severity of injury to a moderate level, corresponding to a score of 2. The 4 mg/kg/day MgT group demonstrated only mild myocardial damage, receiving a score of 1. Consequently, the higher MgT dose showed the greatest apparent reduction in histological injury among the treatment groups.
The histological images presented in the article further illustrate the differences among experimental groups. The normal cardiac tissue showed relatively preserved myocardial organization, whereas the toxic-control tissue demonstrated prominent structural disruption. The amlodipine and 2 mg/kg MgT groups displayed intermediate levels of damage, while tissue from animals treated with 4 mg/kg MgT showed substantially better preservation of myocardial structure. These microscopic observations were consistent with the biochemical measurements, particularly the restoration of antioxidant markers and reduction in MDA [1].
Overall, the study found that magnesium taurate attenuated the cardiovascular effects associated with chronic CdCl₂ exposure in rats. MgT reduced elevated systolic and diastolic blood pressure, restored myocardial antioxidant defenses, decreased lipid peroxidation, and reduced the severity of histological cardiac injury. The 4 mg/kg/day dose generally produced the strongest response, suggesting a dose-related improvement across several of the measured outcomes. The investigators proposed that these effects could reflect the complementary cardiovascular actions of magnesium and taurine, including modulation of vascular function, calcium handling, nitric oxide signaling, blood pressure, and antioxidant defenses. The discussion emphasized that magnesium can influence vascular smooth-muscle contraction and endothelial function, while taurine may affect nitric oxide, the renin–angiotensin system, and oxidative defense mechanisms. The researchers ultimately concluded that MgT protected against CdCl₂-associated hypertension and myocardial oxidative injury by improving blood pressure and restoring antioxidant defenses [1].
2) The results of the study by Choudhary and Bodakhe demonstrated that chronic CdCl₂ administration successfully produced a hypertensive and cataractogenic state in the rats and that magnesium taurate substantially counteracted these effects. The hypertension control animals receiving CdCl₂ alone developed progressive elevations in both systolic and diastolic blood pressure over the six-week experimental period. SBP and DBP were significantly higher than those of the normal group, In contrast, animals treated concurrently with MgT at either 3 or 6 mg/kg/day experienced significant reductions in both SBP and DBP relative to the hypertension control group. Amlodipine likewise lowered blood pressure, although the research team reported that MgT demonstrated a stronger antihypertensive effect than the standard treatment. Heart rate did not differ significantly among the experimental groups throughout the six-week period, indicating that the blood-pressure effects of MgT were not accompanied by a statistically significant alteration in heart rate [2].
The ophthalmologic findings showed a clear relationship between CdCl₂ exposure and cataract progression. Cataract onset was first observed after approximately four weeks of treatment. By the end of six weeks, all lenses in the normal group remained clear, whereas the hypertension control group exhibited substantial cataract development. Specifically, 41.66% of lenses in the CdCl₂-treated hypertension group were classified as stage 2, 50% were stage 3, and 8.33% were stage 4. No lenses in this group remained clear at the end of the experiment. Treatment with MgT markedly slowed this progression. In the 3-mg/kg MgT group, most lenses remained in stages 1 and 2, with only a small proportion reaching stage 3. The protective effect was particularly pronounced at 6 mg/kg/day: 66.66% of lenses remained at stage 1 and 33.33% were stage 2, while none progressed to stages 3 or 4. Amlodipine also reduced cataract progression, but the higher MgT dose produced the most pronounced delay. These findings indicate a dose-related protective effect of MgT against the development of hypertension-associated cataract [2].

 

Figure 2: Changes in cataract incidence and the stage of the cataracts following treatment.
Photographic examination of isolated lenses provided additional evidence of this protective effect. Lenses from CdCl₂-treated hypertension-control animals were visibly more opaque than those from normal rats. Both MgT-treated groups and the amlodipine group demonstrated reduced lens opacity relative to the hypertension control group. The reduction in visible cloudiness corresponded with the ophthalmoscopic staging results and supported the conclusion that MgT slowed the structural progression of cataract formation. The biochemical findings provided a possible explanation for this preservation of lens transparency. CdCl₂ administration produced a significant deterioration of antioxidant defenses in both serum and lens tissue. CAT, SOD, GPx, and GSH were all significantly reduced in the hypertension control group compared with normal animals, while MDA, a marker of lipid peroxidation, was significantly increased. MgT treatment reversed these abnormalities, significantly increasing CAT, SOD, GPx, and GSH while decreasing MDA. The 6-mg/kg MgT treatment produced the strongest antioxidant response and was described by the researchers as having more pronounced antioxidant effects than either the 3-mg/kg MgT treatment or amlodipine.
CdCl₂ exposure also substantially affected lens protein content and electrolyte homeostasis. Total lens protein decreased from 538.7 in normal animals to 329.8 in the hypertension control group, while soluble protein decreased from 427.7 to 266.8. Both MgT doses significantly increased total and soluble protein compared with the hypertension control. The higher MgT dose produced the greatest restoration, with total protein increasing to 490.2 and soluble protein to 389.2. The hypertension control mals also demonstrated significant disturbances in Na⁺, K⁺, and Ca²⁺ concentrations in both serum and lens tissue. Serum and lens Na⁺ increased, K⁺ decreased, and Ca²⁺ shifted in opposite directions, with serum Ca²⁺ decreasing while lens Ca²⁺ increased. MgT significantly corrected these abnormalities. At 6 mg/kg/day, serum Na⁺ decreased to 140.0 mEq/L, K⁺ increased to 4.19 mEq/L, and Ca²⁺ increased to 1.22 mg/dL, while lens Na⁺ declined to 108.30 mEq/L, K⁺ increased to 4.05 mEq/L, and Ca²⁺ decreased to 3.31 mg/dL [2].
Finally, CdCl₂ significantly impaired the activity of both Ca²⁺ ATPase and Na⁺/K⁺ ATPase in the lens. MgT treatment significantly increased the activity of both enzymes compared with the hypertension control group, with the higher MgT dose producing the strongest restoration. The research team interpreted these findings as evidence that MgT helped re-establish the ATP-dependent ion-transport mechanisms necessary for maintaining lens electrolyte balance and transparency. The overall results therefore showed that MgT acted across several interconnected pathological pathways: it reduced CdCl₂-associated hypertension, restored systemic and lenticular antioxidant defenses, reduced lipid peroxidation, preserved lens proteins, normalized Na⁺, K⁺, and Ca²⁺ concentrations, and restored Ca²⁺ ATPase and Na⁺/K⁺ ATPase activity. The researchers consequently concluded that MgT delayed cataractogenesis in this experimental model and appeared to provide broader protective effects than amlodipine across blood pressure, oxidative stress, electrolyte balance, and lens ATPase function. However, the investigators acknowledged an important limitation: the study did not include a group receiving taurine alone, so the individual contribution of taurine versus magnesium within the MgT complex could not be directly determined [2].

 

Disclaimer

**LAB USE ONLY**
*This information is for educational purposes only and does not constitute medical advice. THE PRODUCTS DESCRIBED HEREIN ARE FOR RESEARCH USE ONLY. All clinical research must be conducted with oversight from the appropriate Institutional Review Board (IRB). All preclinical research must be conducted with oversight from the appropriate Institutional Animal Care and Use Committee (IACUC) following the guidelines of the Animal Welfare Act (AWA).

Citations

[1] Shrivastava P, Choudhary R, Nirmalkar U, et al. Magnesium taurate attenuates progression of hypertension and cardiotoxicity against cadmium chloride-induced hypertensive albino rats. J Tradit Complement Med. 2018;9(2):119-123. Published 2018 Jun 2. doi:10.1016/j.jtcme.2017.06.010

[2] Choudhary R, Bodakhe SH. Magnesium taurate prevents cataractogenesis via restoration of lenticular oxidative damage and ATPase function in cadmium chloride-induced hypertensive experimental animals. Biomed Pharmacother. 2016;84:836-844. doi:10.1016/j.biopha.2016.10.012

 

Magnesium Taurate is sold for laboratory research use only. Terms of sale apply. Not for human consumption, nor medical, veterinary, or household uses. Please familiarize yourself with our Terms & Conditions prior to ordering.